Miami Cardiac & Vascular Institute announced the implementation of Philips’ Ingenia Ambition 1.5T MR, the world’s first magnetic resonance imaging (MRI) system to enable helium-free operations. The technology offers cutting-edge imaging techniques that deliver high-quality images faster while providing an improved, more comfortable experience for patients, according to Philips.

Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company's new one-vial Oncardia (ethylenedicysteine-glucosamine) kits. The 60-patient trial study is being conducted in the U.S.

Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime. However, in a new study from UBC Okanagan and Duke University, researchers have developed a system they say may improve the ability to maximize radiation doses to cancer tissues while minimizing exposure to healthy ones.

Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first commercial production of Axumin in Belgium occurred recently, with the first Belgian patients being dosed. This follows the first administration of Axumin in Luxembourg earlier this year. Axumin is the first and only positron emission tomography (PET) imaging agent approved in the European Union for use in men with suspected recurrent prostate cancer. Axumin is commercially available in Belgium, Luxembourg, Italy, France, Norway, the Czech Republic, The Netherlands, United Kingdom and Austria, with further European countries set to follow soon.

Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a magnetic resonance imaging (MRI) ablation center for treating cardiac arrhythmias.

Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy after chemotherapy, even when all traces of the cancer appear to have gone. These findings are according to late-breaking results presented at the European Society for Radiotherapy and Oncology (ESTRO) 38 conference, April 26-30 in Milan, Italy.

Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S. Department of Energy (DOE) Under Secretary for Nuclear Security and Administrator of the National Nuclear Security Administration (NNSA) Lisa Gordon-Hagerty, Lantheus Medical Imaging President and CEO Mary Heino and Janesville City Manager Mark Freitag joined Shine founder and CEO, Greg Piefer, and the Shine team to celebrate the milestone.